Switching From Reference Adalimumab to Biosimilar Shows No Major Differences in Patients With RA, PsA - Prabadin Corp

https://prabadinews.com/

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938

Switching From Reference Adalimumab to Biosimilar Shows No Major Differences in Patients With RA, PsA

Health

August 28, 2025

By AdminPrabadin - 2 days ago

0

Biosimilars can be a more affordable and accessible treatment option for patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

administrator